ELITE PHARMACEUTICALS INC /NV/ Quarterly Common Stock, Shares, Issued from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Common Stock, Shares, Issued history and growth rate from Q1 2011 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Common Stock, Shares, Issued for the quarter ending September 30, 2024 was 1.07B shares, a 5.36% increase year-over-year.
Common Stock, Shares, Issued, Quarterly (shares)
Common Stock, Shares, Issued, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 1.07B +54.4M +5.36% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 1.07B +54.4M +5.36% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 1.07B +54.4M +5.36% Mar 31, 2024 10-Q 2024-11-14
Q4 2023 1.02B +3.87M +0.38% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 1.01B 0 0% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 1.01B +2.63M +0.26% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 1.01B +2.63M +0.26% Mar 31, 2023 10-K 2024-07-01
Q4 2022 1.01B +2.63M +0.26% Dec 31, 2022 10-Q 2023-02-14
Q3 2022 1.01B +2.63M +0.26% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 1.01B 0 0% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 1.01B +2.11M +0.21% Mar 31, 2022 10-K 2024-07-01
Q4 2021 1.01B +2.11M +0.21% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 1.01B +2.11M +0.21% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 1.01B +170M +20.2% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 1.01B +169M +20.1% Mar 31, 2021 10-K 2022-06-29
Q4 2020 1.01B +175M +21% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 1.01B +176M +21.2% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 841M +12.1M +1.46% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 841M +15.6M +1.89% Mar 31, 2020 10-K 2021-06-14
Q4 2019 834M +13.5M +1.64% Dec 31, 2019 10-Q 2020-02-10
Q3 2019 833M +16M +1.96% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 829M +24.3M +3.03% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 825M +22.3M +2.78% Mar 31, 2019 10-K 2020-06-30
Q4 2018 821M +31.7M +4.02% Dec 31, 2018 10-Q 2019-02-11
Q3 2018 817M +30.9M +3.93% Sep 30, 2018 10-Q 2018-11-09
Q2 2018 805M +23.9M +3.06% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 803M -125M -13.5% Mar 31, 2018 10-K 2019-06-21
Q4 2017 789M -122M -13.4% Dec 31, 2017 10-Q 2018-02-09
Q3 2017 786M -108M -12% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 781M +49.8M +6.82% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 928M +216M +30.4% Mar 31, 2017 10-K 2018-06-14
Q4 2016 911M +223M +32.4% Dec 31, 2016 10-Q 2017-02-09
Q3 2016 894M +212M +31.1% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 731M +71M +10.8% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 712M +80.4M +12.7% Mar 31, 2016 10-K 2017-06-14
Q4 2015 688M +79.2M +13% Dec 31, 2015 10-Q 2016-02-09
Q3 2015 682M +90M +15.2% Sep 30, 2015 10-Q/A 2015-12-30
Q2 2015 660M +92M +16.2% Jun 30, 2015 10-Q/A 2015-12-30
Q1 2015 631M +70.9M +12.7% Mar 31, 2015 10-K 2016-06-15
Q4 2014 609M +95.7M +18.7% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 592M +96.9M +19.6% Sep 30, 2014 10-Q 2014-11-14
Q2 2014 568M +172M +43.5% Jun 30, 2014 10-Q 2014-08-14
Q1 2014 560M +186M +49.6% Mar 31, 2014 10-K 2015-06-15
Q4 2013 513M +163M +46.5% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 495M +145M +41.5% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 396M +49.6M +14.3% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 374M +42.8M +12.9% Mar 31, 2013 10-K 2014-06-30
Q4 2012 350M +85.5M +32.3% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 350M +94.9M +37.2% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 346M +103M +42.3% Jun 30, 2012 10-Q 2012-08-14
Q1 2012 332M +151M +83.7% Mar 31, 2012 10-K 2013-06-21
Q4 2011 265M Dec 31, 2011 10-Q 2012-02-14
Q3 2011 255M Sep 30, 2011 10-Q 2011-11-14
Q2 2011 243M Jun 30, 2011 10-Q/A 2011-08-19
Q1 2011 181M Mar 31, 2011 10-K 2012-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.